Researchers from major universities in the U.S. have developed specific tests to identify cancer biomarkers in patients with dermatomyositis - a systemic inflammatory disease associated with increased risk of malignancy. According to study findings published in the American College of Rheumatology (ACR) journal, Arthritis & Rheumatism, the assays detect antibodies against anti-transcriptional intermediary factor-1 (TIF-1gamma) and nuclear matrix protein NXP-2. Patients with dermatomyositis experience muscle weakness, skin inflammation, and sometimes inflammation of the lung...
No comments:
Post a Comment